Article

Acute Cellular Rejection Predominated by Monocytes Is a Severe Form of Rejection in Human Renal Recipients With or Without Campath‐1H (Alemtuzumab) Induction Therapy

Geisinger Medical Center, Данвил, Pennsylvania, United States
American Journal of Transplantation (Impact Factor: 6.19). 04/2005; 5(3):604-7. DOI: 10.1111/j.1600-6143.2004.00712.x
Source: PubMed

ABSTRACT Campath-1H has been used successfully for induction and has resulted in a low rate of acute cellular rejection (ACR) in renal transplantation in combination with various postoperative immunosuppression regimens. This study was undertaken to investigate the extent of monocyte involvement in ACR, with or without Campath-1H induction. We found that monocytes represented the majority of inflammatory cells in grades Ib or higher ACR, but not with Ia type of ACR, regardless of the status of Campath-1H induction. Cases of ACR, following Campath-1H induction, appear to demonstrate a 'pure form' of monocytic ACR, whereas monocytes were mixed with many other types of inflammatory cells in the cases of ACR in the absence of Campath-1H induction. In addition with Campath-1H induction, the cases of monocyte-predominant ACR were found to uniformly exhibit a good response to corticosteroid treatment. We conclude that monocyte-predominate ACR may represent a severe form of rejection, with or without Campath-1H treatment.

Download full-text

Full-text

Available from: Sayeed K Malek, Sep 11, 2014
0 Followers
 · 
208 Views
 · 
12 Downloads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We undertook a study to ascertain the relationship between the presence of CD20-positive B-lymphocytes in renal allografts undergoing acute cellular rejection and graft survival. We identified 27 patients transplanted between January 1, 1998 and December 31, 2001, with biopsy-proven Banff 1-A or Banff 1-B rejection in the first year after transplantation, and stained the specimens for CD20 and C4d. At least 4 years of follow-up data were available for each patient studied. Six patients had CD20-positive B-cell clusters in the interstitium, and 21 patients were negative for CD20 infiltrates. The CD20-positive group was significantly more likely to have steroid-resistant rejection and reduced graft survival compared to CD20-negative controls. This study supports prospective identification of CD20-positive B-cell clusters in biopsy-proven rejection and offers a therapeutic rationale for a trial of monoclonal anti-CD20 antibody in such patients.
    American Journal of Transplantation 10/2005; 5(9):2248-52. DOI:10.1111/j.1600-6143.2005.01009.x · 6.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Much attention has recently been placed on transplanting anti-Human Leukocyte Antigen (HLA) sensitized patients and using ABO-incompatible organs. To achieve this goal, the antibodies must be removed. It is therefore timely to provide a review that updates the current literature on drugs and modalities being used including intravenous immunoglobulin-G, mycophenolate mofetil, sirolimus, Campath, Protein A immunoabsorption, and rituximab. Recent findings: The most important recent study, a randomized trial of intravenous immunoglobulin-G versus placebo, confirmed the efficacy of intravenous immunoglobulin-G for desensitization. Campath appears to be unable to prevent antibody-mediated rejection and therefore is probably not suitable for desensitization. Animal data suggest that immunoabsorption columns might be working through the systemic exposure of Protein A. Rituximab, a B-cell specific antibody, appears to be safe and to have some efficacy as a sole agent in elimination of alloantibodies but most likely will require combination therapy. Newer agents such as humanized anti-CD20 and drugs targeting other B-cell antigens such as BAFF (B-cell Activation Factor of the TNF Family) and APRIL (A PRoliferation-Inducing Ligand) are being developed. Summary: Although many reports are appearing that demonstrate successful transplants, there is a major deficiency in controlled clinical trials with these drugs. Focus over the near future should be to prove the efficacy through the use of randomized trials.
    Current Opinion in Organ Transplantation 11/2005; 10(4):279-283. DOI:10.1097/01.mot.0000183248.12710.16 · 2.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immunosuppressive drugs have been traditionally developed to prevent acute rejection and to improve short-term kidney transplant outcomes. There is still a medical need to improve outcomes among subgroups of patients at higher risk for graft loss and to reduce cardiovascular, infectious and malignancy-associated morbidity and mortality, and improve long-term adherence. Several new immunosuppressive agents and formulations are undergoing clinical investigation and are discussed in this review.A modified release tacrolimus formulation (MR4) for once-daily administration is undergoing phase III trials. It has been developed to be administered de novo or for maintenance using the same therapeutic target tacrolimus trough concentrations as for the original formulation. Belatacept (LEA29Y), a second generation cytotoxic-T-lymphocyte-associated antigen immunoglobulin (CTLA4-Ig), blocks the interaction between CD80/86 and CD28 costimulatory pathways. In phase II trials, belatacept was as effective as ciclosporin (cyclosporine) when administered in combination with basiliximab, mycophenolate mofetil (MMF) and corticosteroids. Currently, belatacept is undergoing phase III trials including one study in recipients of organs from expanded criteria donors. Inhibitors of the Janus protein tyrosine kinase (JAK)-3 show some selectivity for cells of the lymphoid lineage and have been shown to be effective in late preclinical transplant models. The most frequent adverse effects have been related to nonspecific binding to JAK2 kinases. CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials. FK778 also shows antiviral activities that have been tested in patients with polyomavirus nephropathy. Fingolimod (FTY720), a synthetic sphingosine phosphate receptor modulator that reduces the recirculation of lymphocytes to blood and peripheral tissues including inflammatory lesions and graft sites is undergoing phase III trials. Although the efficacy of fingolimod is similar to MMF in patients receiving full doses of ciclosporin, safety issues such as a negative chronotropic effect, macular oedema, pulmonary adverse reactions and graft function resulted in premature discontinuation of the development programme for kidney transplantation. Because there was no clear clinical benefit over treatment options, the clinical development programme of FK778 was discontinued.Finally, a new evolving strategy with powerful induction-induced prolonged T-cell depletion followed by low-dose immunosuppressive monotherapy is showing promising results.
    Drugs 02/2006; 66(13):1665-84. DOI:10.2165/00003495-200666130-00002 · 4.13 Impact Factor
Show more